Table 1.
Pre-clinical and clinical studies with Tα1 in cancer and chronic hepatitis B and C.
| Pathology | Study | Treatment | Efficacy | References |
|---|---|---|---|---|
| Melanoma | Pre-clinical | Tα1 monotherapy | Evidence of treatment efficacy | (15, 30) |
| No significant evidence of treatment efficacy | (17–19, 31, 33–35) | |||
| Tα1 in combination therapy with: αβ-IFN IL-2 Cy and αβ-IFN anti-PD-1 Ab |
Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy |
(17–19) (19) (20) (30) |
||
| Tα1 fusion proteins: - concatemer - thymopentin - RGDR - iRGD - Fc |
Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy |
(31) (32) (33) (34) (35) |
||
| Clinical | Tα1 in combination therapy with: - dacarbazine and IL-2 - dacarbazine and IFNα - dacarbazine and IFNα - dacarbazine |
Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy |
(25) (26) (27, 29) (28, 29) |
|
| Chronic hepatitis B | Clinical | Tα1 monotherapy | Evidence of treatment efficacy | (40, 42–44) |
| No evidence of treatment efficacy | (46, 47) | |||
| Tα1 in combination therapy with: - IFNα - pegylated IFNα - famciclovir - lamivudine - entecavir |
Evidence of treatment efficacy No evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy No evidence in HBV-related compensated cirrhosis |
(48–51) (52) (62) (63) (64) (65) |
||
| Chronic hepatitis C | Clinical | Tα1 monotherapy | No evidence of treatment efficacy | (54, 55) |
| Tα1 in combination therapy with: - IFNα - IFN and ribavirin |
Evidence of treatment efficacy Evidence of treatment efficacy No evidence in on-treatment viral response |
(53, 56–58) (66–69) (70) |
||
| HCC | Clinical | Tα1 monotherapy | Evidence of treatment efficacy | (71, 72) |
| Tα1 in combination therapy with: - TACE - lamivudine - sorafenib |
Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy |
(73–75) (76) (77) |
||
| Lung cancer | Pre-clinical | Tα1 monotherapy | Evidence of treatment efficacy | (19, 85–87, 89) |
| No significant evidence of treatment efficacy | (17, 24, 34, 80, 84) | |||
| Tα1 in combination therapy with: - αβ-IFN - Cy and αβ-IFN - Cy and IL-2 - gemcitabine |
Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy Evidence of treatment efficacy |
(17, 19) (80) (24) (84) |
||
| Tα1 fusion protein: - iRGD |
Evidence of treatment efficacy | (34) | ||
| Clinical | Tα1 monotherapy | Evidence of treatment efficacy | (79) | |
| Tα1 in combination therapy with: - cisplatin, etoposide, IFNα2a - ifosfamide, IFNα - cisplatin, vinorelbine or gemcitabine |
Evidence of treatment efficacy Trend toward treatment efficacy Evidence of treatment efficacy |
(81) (82) (83) |